Evan J. Lipson

Dec 4, 2024 | targetedonc.com | Evan J. Lipson

Evan Lipson, MD, an associate professor of oncology at John Hopkins School of Medicine and a head and neck oncologist at John Hopkins Medicine, discusses the evolving treatment landscape for advanced melanoma. During a Case-Based Roundtable meeting, Lipson and participants talked about the complexity of choosing the right therapy for each patient at the appropriate time due to the abundance of new treatment options.

Nov 21, 2024 | targetedonc.com | Evan J. Lipson

Evan Lipson, MD, an associate professor of oncology at John Hopkins School of Medicine and a head and neck oncologist at John Hopkins Medicine, discusses feedback he’s received from colleagues at Case-Based Roundtable events about patients with melanoma. After meeting with oncologists participating in the roundtable discussion, Lipson says that much of the conversation revolved around the response durability of immunotherapy.

Aug 13, 2024 | brnw.ch | Georgina V. Long |Evan J. Lipson |F. Stephen Hodi

Authors' Disclosures of Potential Conflicts of InterestThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.

May 26, 2023 | obroncology.com | Allison Warner |Evan J. Lipson |Kim Margolin

Promising results for the use of mRNA vaccines in the treatment of melanoma have patients asking when and if it is an option for them. However, many questions about the “bespoke” approach remain unanswered.

May 3, 2023 | obroncology.com | Kim Margolin |Allison Warner |Evan J. Lipson

Mucosal melanoma remains challenging to treat. Historically, these patients have had poorer response to immunotherapy than those with cutaneous melanoma.